Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator‐mandated cohort postauthorization safety study in Denmark, Norway, and Sweden
Authors:
- Vera EhrensteinVEVera Ehrenstein
- Uffe Heide‐JørgensenUHUffe Heide‐Jørgensen
- Morten SchiødtMSMorten Schiødt
- Olof AkreOAOlof Akre
- Bente Brokstad HerlofsonBHBente Brokstad Herlofson
- Cecilia Larsson WexellCWCecilia Larsson Wexell
- Sven Erik NørholtSNSven Erik Nørholt
- Steinar TretliSTSteinar Tretli
- Anders KjellmanAKAnders Kjellman
- Kimberly A. LoweKLKimberly A. Lowe
Open Access
Abstract
BACKGROUND: Osteonecrosis of the jaw (ONJ) is an adverse effect of antiresorptive treatment. This study estimated incidence proportions and incidence rates of ONJ in cancer patients with bone metastases from solid tumors treated for the prevention of skeletal‐related events in routine clinical practice.METHODS: This cohort study in Denmark, Norway, and Sweden in 2011‐2018 included 3 treatment cohorts: a denosumab inception cohort (DEIC), a zoledronic acid inception cohort (ZAIC), and a denosumab‐switch cohort (DESC). The authors estimated 1‐ to 5‐year incidence proportions and incidence rates of ONJ overall, by cancer site (breast, prostate, or other solid tumor), and by country. ONJ diagnoses were confirmed by adjudication.RESULTS: There were 1340 patients in the DEIC, 1352 in the ZAIC, and 408 in the DESC. The median ages of the 3 cohorts were 70, 69, and 70 years, respectively; the proportions of men were 72.6%, 53.8%, and 48.3%, respectively; and the median follow‐up was 19.8, 12.9, and 13.3 months, respectively. The 5‐year incidence proportions of ONJ were 5.7% (95% confidence interval [CI], 4.4%‐7.3%) in the DEIC, 1.4% (95% CI, 0.8%‐2.3%) in the ZAIC, and 6.6% (95% CI, 4.2%‐10.0%) in the DESC. The corresponding ONJ incidence rates per 100 person‐years were 3.0 (95% CI, 2.3‐3.7), 1.0 (95% CI, 0.6‐1.5), and 4.3 (95% CI, 2.8‐6.3). Incidence proportions and incidence rates were highest in patients with prostate cancer and in Denmark.CONCLUSIONS: This study provides estimates of the risk of medically confirmed ONJ among patients initiating denosumab or zoledronic acid in routine clinical practice in 3 Scandinavian countries. The results varied by cancer site and by country.LAY SUMMARY: Denosumab and zoledronic acid reduce the risk of bone fractures, pain, and surgery in patients with advanced cancers involving bone. Osteonecrosis of the jaw (ONJ)—death of a jawbone—is a known side effect of treatment with denosumab or zoledronic acid. The authors examined almost 2900 denosumab‐ or zoledronic acid–treated patients with cancer in Denmark, Norway, and Sweden. Over the course of 5 years, ONJ developed in 5.7% of the patients whose initial treatment was denosumab, in 1.4% of the patients whose initial treatment was zoledronic acid, and in 6.6% of the patients who switched from zoledronic acid to denosumab.Keywords
This publication has 21 references indexed in Scilit:
- Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw – work in progress and challengesClinical Epidemiology, 2015
- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 UpdateJournal of Oral and Maxillofacial Surgery, 2014
- Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trialsOncology Letters, 2014
- Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysisCancer Treatment Reviews, 2013
- Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug DevelopmentClinical Pharmacology & Therapeutics, 2011
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaJournal of Clinical Oncology, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 UpdateJournal of Oral and Maxillofacial Surgery, 2009
- Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studiesHepatology, 2006